Calidi Biotherapeutics (CLDI) News Today $0.40 0.00 (-0.80%) Closing price 04:00 PM EasternExtended Trading$0.40 +0.00 (+0.25%) As of 05:17 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsTrendsBuy This Stock CLDI Latest News All Sources Trusted Sources MarketBeat Benzinga Bloomberg GlobeNewswire GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 Time Period Calidi Biotherapeutics, Inc: Calidi Biotherapeutics Reports First Quarter 2025 Financial Results and Recent Operational HighlightsMay 16, 2025 | finanznachrichten.deCalidi Biotherapeutics Strengthens Leadership Team and Advances Antitumor Virotherapy Platform with New CEO and Chief Medical Officer AppointmentsMay 16, 2025 | nasdaq.comCalidi Biotherapeutics Reports First Quarter 2025 Financial Results and Recent Operational HighlightsMay 15, 2025 | tmcnet.comCalidi Biotherapeutics Announces IL15 Superagonist as First Payload to be Delivered by Systemic Antitumor Virotherapy Platform at AACR Annual MeetingApril 28, 2025 | finance.yahoo.comCalidi reports inducement grant unders NYSE American guideApril 26, 2025 | markets.businessinsider.comCalidi Biotherapeutics Reports Inducement Grant Under NYSE American LLC Company Guide Section 711April 25, 2025 | globenewswire.comCalidi appoints Eric Poma as CEO, directorApril 24, 2025 | markets.businessinsider.comCalidi announces FDA clearance of IND application for CLD-201April 18, 2025 | markets.businessinsider.comCalidi Biotherapeutics Announces FDA Clearance of IND Application for CLD-201 in Solid TumorsApril 17, 2025 | markets.businessinsider.comCalidi appoints Guy Travis Clifton as CMO, Consultant, AdvisorApril 10, 2025 | markets.businessinsider.comCalidi Biotherapeutics Announces Appointment of Guy Travis Clifton, MD as Chief Medical Officer, Consultant and AdvisorApril 10, 2025 | finance.yahoo.comCalidi Biotherapeutics Reports Fourth Quarter and Full-Year 2024 Financial Results and Recent Operational HighlightsMarch 31, 2025 | markets.businessinsider.comCalidi Biotherapeutics Announces Closing of $3.9 Million Registered Direct Offering and Concurrent Private PlacementMarch 31, 2025 | globenewswire.comCalidi Biotherapeutics Provides Update On Phase 1 Trial Of CLD-101 For Recurrent GliomaMarch 29, 2025 | nasdaq.comCalidi prices 3.33M shares at 65c in registered direct offeringMarch 29, 2025 | markets.businessinsider.comCalidi Biotherapeutics Announces Pricing of $3.9 Million Registered Direct Offering and Concurrent Private PlacementMarch 28, 2025 | globenewswire.comCalidi, City of Hope provide update on Phase 1 trial with CLD-101March 27, 2025 | markets.businessinsider.comIBN Coverage: Calidi Biotherapeutics (NYSE American: CLDI) Reports Promising Preclinical Results for RTNova Virotherapy PlatformMarch 11, 2025 | finance.yahoo.comCalidi Biotherapeutics (NYSE American: CLDI) Reports Promising Preclinical Results for RTNova Virotherapy PlatformMarch 11, 2025 | theglobeandmail.comCalidi announces ability to deliver transient gene therapy to tumorsMarch 10, 2025 | markets.businessinsider.comCalidi Biotherapeutics Announces Demonstrated Ability To Deliver Transient Gene Therapy (Payload) To Tumors Using Systemic PlatformMarch 10, 2025 | globenewswire.comCalidi Biotherapeutics and OS Therapies Interviews to Air on the RedChip Small Stocks, Big Money Show on Bloomberg TVFebruary 28, 2025 | finanznachrichten.deCalidi commences recruitment for multiple dose CLD-101 trialFebruary 24, 2025 | markets.businessinsider.comCalidi Biotherapeutics Announces Commencement of Recruitment for Multiple Dose CLD-101 Trial in Patients with Newly Diagnosed High Grade Glioma at Northwestern University HospitalFebruary 24, 2025 | globenewswire.comCalidi Biotherapeutics expands stock offering capacityFebruary 5, 2025 | msn.comJoin Calidi Biotherapeutics’ Exclusive Live Investor Webinar and Q&A Session on February 5January 30, 2025 | markets.businessinsider.comCLDI Stock Plummets to 52-Week Low at $0.6 Amid Market TurbulenceJanuary 30, 2025 | msn.comJoin Calidi Biotherapeutics' Exclusive Live Investor Webinar and Q&A Session on February 5January 29, 2025 | globenewswire.comCalidi announces termination of standby equity purchase agreementJanuary 29, 2025 | markets.businessinsider.comCalidi Biotherapeutics Announces Bolstered Cash Balance and Termination of its Standby Equity Purchase AgreementJanuary 28, 2025 | globenewswire.comCLDI stock touches 52-week low at $0.73 amid market challengesJanuary 22, 2025 | msn.comCalidi Biotherapeutics (NYSE American: CLDI) Prices $4.25 Million Public OfferingJanuary 13, 2025 | theglobeandmail.comCalidi to present new data on systemic virotherapy RTNova platformJanuary 13, 2025 | markets.businessinsider.comCalidi Biotherapeutics Announces Presentation of New Data of Systemic Virotherapy RTNova Platform at the AACR Annual Meeting in April 2025January 13, 2025 | markets.businessinsider.comCalidi Biotherapeutics Prices Offering Of 5 Mln Shares At $0.85/Share, Stock FallsJanuary 10, 2025 | markets.businessinsider.comCalidi Biotherapeutics slumps 29%, prices $4.25M stock offeringJanuary 10, 2025 | msn.comCalidi Biotherapeutics Announces Closing of $4.25 Million Public Offering of Common StockJanuary 10, 2025 | globenewswire.comCalidi Biotherapeutics Announces Pricing of $4.25 Million Public Offering of Common StockJanuary 10, 2025 | globenewswire.comCalidi announces common stock offering, no amount givenJanuary 9, 2025 | markets.businessinsider.comCalidi Biotherapeutics Announces Proposed Public OfferingJanuary 8, 2025 | globenewswire.comAllan Camaisa Sells 10,000 Shares of Calidi Biotherapeutics, Inc. (NYSE:CLDI) StockDecember 19, 2024 | insidertrades.comCalidi Biotherapeutics (NYSE American: CLDI) at the Forefront of Cancer Treatment InnovationDecember 13, 2024 | theglobeandmail.comCalidi Biotherapeutics prices $7.5M secondary offeringDecember 12, 2024 | msn.comCalidi Biotherapeutics (NYSE American: CLDI) Data Demonstrates Potential of Innovative Solutions to Revolutionize Cancer CareDecember 9, 2024 | theglobeandmail.comCalidi Biotherapeutics (NYSE American: CLDI) Showcases RTNova Virotherapy BreakthroughNovember 19, 2024 | theglobeandmail.comCalidi Biotherapeutics Reveals Promising Virotherapy DataNovember 18, 2024 | markets.businessinsider.comCalidi Biotherapeutics: Innovative Cancer Treatment with Promising Clinical Results but Financial ChallengesNovember 18, 2024 | markets.businessinsider.comCalidi Biotherapeutics Presents Data Supporting RTNova Systemic Technology to Target Metastatic Lung CancerNovember 18, 2024 | markets.businessinsider.comCalidi Biotherapeutics Announces Closing of $7.5 Million Public Offering of Common StockNovember 15, 2024 | globenewswire.comCalidi prices 4.4M shares at $1.69 in public offeringNovember 14, 2024 | markets.businessinsider.com Get Calidi Biotherapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for CLDI and its competitors with MarketBeat's FREE daily newsletter. Email Address CLDI Media Mentions By Week CLDI Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. CLDI News Sentiment▼0.001.03▲Average Medical News Sentiment CLDI News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. CLDI Articles This Week▼01▲CLDI Articles Average Week Get Calidi Biotherapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for CLDI and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies Biodexa Pharmaceuticals News Today Adverum Biotechnologies News Today Opus Genetics News Today Xilio Therapeutics News Today RenovoRx News Today PMV Pharmaceuticals News Today Karyopharm Therapeutics News Today Anebulo Pharmaceuticals News Today Connect Biopharma News Today Avalo Therapeutics News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NYSE:CLDI) was last updated on 5/28/2025 by MarketBeat.com Staff From Our PartnersJuly 2025 Rule Change to Impact Retirement InvestorsThere's a massive change from a new rule going into effect this July. And it's one the Big Banks are alread...Premier Gold Co | SponsoredF1 Engineering Powers This Electric Marine MotorThe future of marine propulsion has arrived - powered by F-1 grade engineering. In collaboration with McLar...The Tomorrow Investor | SponsoredTrump Predicts Dollar DownfallREAD THIS VERY CAREFULLY: If you have $100,000 or more saved for retirement, this may make you VERY angry... ...Augusta Precious Metals | SponsoredTrump Quietly Planning $15 Trillion Crypto ShockerMost investors are still unaware, but I believe a new White House action may have quietly opened the floodgate...Paradigm Press | SponsoredThe biggest threat isn’t ChinaWhile the headlines focus on AI models and chip speed, Elon Musk is investing in the material side of the stor...True Market Insiders | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredGet Your Bank Account “Fed Invasion” Ready with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredThe trade war twist nobody saw comingThe media and financial pundits are all misreading Trump’s actions. They think Trump wants to make Canada t...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Calidi Biotherapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Calidi Biotherapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy CLDI Stock Free CLDI Stock Alerts